AGC builds on Provention partnership with diabetes mAb production
AGC Biologics' Bothwell, Washington site is commercially manufacturing Provention Bio's type 1 diabetes (T1D) monoclonal antibody Tzield (teplizuma...
AGC Biologics' Bothwell, Washington site is commercially manufacturing Provention Bio's type 1 diabetes (T1D) monoclonal antibody Tzield (teplizumab). Provention Bio said it selected AGC Bio to produce Tzield – the first authorized drug that can delay onset T1D – after the contract development manufacturing organization (CDMO) supported the drug ahead of its approval by the US Food and Drug Administration (FDA) in November 2022. Tepilzumab is manufactured in two main stages: the upstream process followed by the downstream process,' Kevin Ingham, general manager of AGC Bio's Seattle campus, told BioProcess Insider.